Fig. 6From: A novel nanobody as therapeutics target for EGFR-positive colorectal cancer therapy: exploring the effects of the nanobody on SW480 cells using proteomics approachInteraction network of gefitinib and the differential expressed proteins. The interactions were represented in different colors including protein–protein interactions are shown in grey, gefitinib-protein interactions in green, and interactions between other chemicals in redBack to article page